local_hospital

Fundacio Assistencial De Mutua De Terrassa Fpc

Address
lock Available on a paid plan

Neurology and Neurodegenerative Disease Research

At Fundacio Assistencial De Mutua De Terrassa Fpc, clinical research in nervous system diseases focuses strongly on Alzheimer’s disease, with studies in early, mild, and dementia stages. These trials are designed to test new treatment options, explore symptom control, and better understand how the disease progresses over time.

  • Early Alzheimer’s disease with biomarkers of inflammation
  • Mild Alzheimer’s disease
  • Treatment of Alzheimer’s disease dementia
  • Evaluating novel therapies aimed at slowing cognitive decline

The site’s Neurology department also contributes to broader efforts in improving diagnosis and treatment response for patients living with progressive brain disorders.

Stroke and Atrial Fibrillation Studies

Research in cardiovascular diseases includes trials for acute ischemic stroke, high-risk transient ischemic attack, and atrial fibrillation. These studies aim to reduce the risk of future stroke and improve prevention strategies for patients who may not be able to use standard anticoagulation treatments.

  • Preventing recurrent ischemic stroke after a recent event
  • Lowering stroke risk in atrial fibrillation
  • Testing safer approaches for patients unsuitable for oral anticoagulation

This area reflects a clear focus on improving long-term protection against serious thromboembolic complications.

Hematology and Blood Cancer Trials

The site is active in hemic and lymphatic diseases, with studies involving acute myeloid leukemia, myelodysplastic syndrome, follicular lymphoma, marginal zone lymphoma, and Waldenström’s macroglobulinemia. The research is centered on testing new cancer treatments and comparing their effectiveness in difficult-to-treat blood cancers.

  • New treatment approaches for AML and IDH1-mutated AML
  • Therapy comparisons in relapsed or refractory lymphoma
  • Options for relapsed/refractory Waldenström’s macroglobulinemia
  • Evaluating treatment safety and disease control in hematologic malignancies

These studies support progress in oncology by seeking better outcomes for patients with relapsed, resistant, or newly diagnosed blood cancers.

Solid Tumor Oncology Research

Within neoplasms, the trials at this site include early-stage breast cancer and advanced ovarian, tubal, or peritoneal cancer. The research aims to understand long-term outcomes after treatment and to evaluate strategies that may improve disease control and survival in women’s cancers.

  • Long-term follow-up in early invasive breast cancer
  • Treatment strategies for advanced ovarian and related gynecologic cancers
  • Assessing relapse patterns and progression-free survival

These studies combine follow-up research with treatment evaluation to help refine care pathways in oncology.

Infectious Disease Research

The site also participates in studies on bacterial infections and mycoses, especially severe community-acquired bacterial pneumonia. This research is focused on improving recovery, testing adjunctive treatment options, and strengthening care for patients with serious respiratory infection.

  • Severe community-acquired bacterial pneumonia
  • Evaluating new supportive treatment approaches
  • Measuring clinical recovery and safety outcomes

These trials contribute to better management of complex infections in a hospital setting.

Site Overview

assignment
65
connected trials
corporate_fare
44
sponsors
science
121
IMPs

Activity Indicator

Last 6 months

4
Trials started
-43% vs previous period.
7
Trials started 6–12 months ago
65
Total trials linked
Highly Active
trending_downDeclining-43%
1
2
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 14 therapeutic areas and 15 of 121 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 119 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
26
Sponsors (total)
44
Active sponsors
23

Sponsor Network

Top 23 by active trials.

lock +22 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +11 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 567 other sites in Spain

description
Trial volume
65
Outperforms 89% of sites
public
Therapeutic diversity
14areas
Outperforms 89% of sites
groups
Sponsor diversity
44sponsors
Outperforms 88% of sites

Therapeutic Area Benchmark — Spain

Select a therapeutic area to compare against other sites in Spain.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Spain

Market Share

Country: Spain

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Fundacio Assistencial De Mutua De Terrassa Fpc

lock Showing 1 of 65 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MK-2214 in Participants with Early Alzheimer's DiseaseMerck Sharp & Dohme LLCPhase IIRecruitingOct 2025

IMP list

lock Showing 1 of 121 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Lenalidomide6Unknown2018-11-152023-09-28

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.